BSE filing, NSE: NATHBIOGEN. Summary written from the filing by ALFA Finder's alert engine.
Nath Bio-Genes (India) Ltd: key numbers
- Share price
- ₹135.03
- Market cap
- ₹256.6 Cr
- Revenue (annual)
- ₹445.1 Cr
- Net profit (annual)
- ₹41.63 Cr
- P/E (TTM)
- 7.0×Sector 28.6×
- Promoter holding
- 45.60%+0.00% QoQ
- FII holding
- 0.18%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Nath Bio-Genes (India) Ltd
All →Nath Bio-Genes (India) Other Announcement
Nath Bio-Genes (India) Limited filed the Compliance Certificate for the quarter ended September 30, 2026, as required under Regulation 74(5) of the SEBI regulations.
Nath Bio-Genes (India) Annual General Meeting
Nath Bio-Genes (India) Ltd held its 33rd AGM on September 24, 2026. Shareholders approved all five resolutions, including a final dividend of ₹2/- per share.
Nath Bio-Genes (India) Annual General Meeting
Nath Bio-Genes (India) Ltd issued notice for its 33rd Annual General Meeting, to be held on September 24, 2026, alongside the Annual Report for FY2025-26.
Nath Bio-Genes (India) ED Probe / Tax Survey
SEBI has initiated a forensic audit of Nath Bio-Genes (India) Ltd for financial years 2020-21 to 2025-26. CNK & Associates LLP has been appointed as the forensic auditor.
- Execution
- FY 2020-21 to 2025-26
Nath Bio-Genes (India) Investor Presentation: Key Takeaways
Nath Bio-Genes reported strong Q1 FY27 results with Revenue and EBITDA growing 15% and 17% YoY respectively. The company continues to focus on high-yield cotton, maize, and paddy seeds.
Nath Bio-Genes (India) Q1 FY27 Results: Net Profit ₹32.3 Cr, Up 14.1% YoY
Nath Bio-Genes (India) Ltd reported revenue from operations of ₹328.4 Cr (+15.8% YoY) and net profit of ₹32.3 Cr (+14.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹32.3 Cr · +14.1% YoY
Other board meeting date announcements
All →Aryaman Capital Markets Board Meeting Date
Aryaman Capital Markets Ltd has scheduled a board meeting on November 12, 2026. The board will consider and approve unaudited financial results for the quarter ended September 2026.
Triveni Enterprises Board Meeting Date
Triveni Enterprises Ltd has scheduled a board meeting on November 13, 2026. The board will consider and approve unaudited financial results for the quarter and half-year ended September 30, 2026.
Polson Board Meeting Date
Polson Ltd will hold a board meeting on November 13, 2026, to approve unaudited financial results. This meeting covers the quarter and half-year ended September 30, 2026.
Escorp Asset Management Board Meeting Date
Escorp Asset Management Limited will hold a board meeting on November 12, 2026. The board will consider and approve unaudited financial results for the quarter ended September 30, 2026.
SBEC Systems (India) Board Meeting Date
SBEC Systems India Ltd has scheduled a board meeting for November 13, 2026. The board will consider unaudited standalone and consolidated financial results for the quarter ended September 2026.
Oxygenta Pharmaceutical Board Meeting Date
Oxygenta Pharmaceutical Limited has scheduled a board meeting for November 10, 2026. The board will primarily consider and approve the unaudited financial results for the quarter and half-year ended September 30, 2026.